

28 Oct 2019 | Analysis

## QUOTED. 28 October 2019. Angela Culhane.

by

The combined market for prostate cancer diagnostics and minimally invasive treatments is expected to reach \$1460m in the next five years, according to a recent Meddevicetracker report. See what UK chief executive of charity Prostate Cancer UK, Angela Culhane, said about it here.

“We need new tests and improvements at each stage of diagnosis, including a more specific test that could follow the PSA test to rule out some false positives before a mpMRI scan. This will most likely be an advanced type of blood test that looks for several markers of cancer, including proteins and genes that are linked to a high risk of cancer.” – Angela Culhane, chief executive, Prostate Cancer UK

- Find out more: [Market Intel: Precision Diagnostics And Focal Treatments Offer Personalized Approach To Prostate Cancer](#)

[Click here](#) for a free trial of *Medtech Insight*